Verve Therapeutics Inc (NASDAQ: VERV) on Tuesday, soared 7.18% from the previous trading day, before settling in for the closing price of $7.52. Within the past 52 weeks, VERV’s price has moved between $4.30 and $19.34.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 126.44%. The company achieved an average annual earnings per share of 22.10%. With a float of $63.10 million, this company’s outstanding shares have now reached $84.64 million.
Let’s determine the extent of company efficiency that accounts for 255 employees. In terms of profitability, gross margin is 73.07%, operating margin of -928.6%, and the pretax margin is -806.35%.
Verve Therapeutics Inc (VERV) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Verve Therapeutics Inc is 25.47%, while institutional ownership is 75.01%. The most recent insider transaction that took place on Dec 02 ’24, was worth 3,130. In this transaction Chief Financial Officer of this company sold 555 shares at a rate of $5.64, taking the stock ownership to the 5,380 shares. Before that another transaction happened on May 14 ’24, when Company’s insider bought 76,000 for $6.26, making the entire transaction worth $475,760. This insider now owns 342,509 shares in total.
Verve Therapeutics Inc (VERV) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.74 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 2.28% during the next five years compared to -67.06% drop over the previous five years of trading.
Verve Therapeutics Inc (NASDAQ: VERV) Trading Performance Indicators
Verve Therapeutics Inc (VERV) is currently performing well based on its current performance indicators. A quick ratio of 13.05 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 27.97.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.46, a number that is poised to hit -0.68 in the next quarter and is forecasted to reach -2.81 in one year’s time.
Technical Analysis of Verve Therapeutics Inc (VERV)
Looking closely at Verve Therapeutics Inc (NASDAQ: VERV), its last 5-days average volume was 1.4 million, which is a drop from its year-to-date volume of 1.72 million. As of the previous 9 days, the stock’s Stochastic %D was 54.68%. Additionally, its Average True Range was 0.65.
During the past 100 days, Verve Therapeutics Inc’s (VERV) raw stochastic average was set at 85.22%, which indicates a significant increase from 81.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.32% in the past 14 days, which was higher than the 92.18% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.25, while its 200-day Moving Average is $5.84. However, in the short run, Verve Therapeutics Inc’s stock first resistance to watch stands at $8.33. Second resistance stands at $8.60. The third major resistance level sits at $8.98. If the price goes on to break the first support level at $7.68, it is likely to go to the next support level at $7.30. Should the price break the second support level, the third support level stands at $7.03.
Verve Therapeutics Inc (NASDAQ: VERV) Key Stats
Market capitalization of the company is 682.39 million based on 84,664K outstanding shares. Right now, sales total 11,760 K and income totals -200,070 K. The company made 6,870 K in profit during its latest quarter, and -50,130 K in sales during its previous quarter.
